SCHEMBL6042226

SCHEMBL6042226

O=C(O)N1CCC(c2ccc(OCC=Cc3ccccc3)cc2)C(O)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 3/20 0.41
PPARD Q03181 2/20 0.41
PPARG P37231 2/20 0.41
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
LMNA P02545 2/20 0.41
POLB P06746 1/20 0.40
MAPK1 P28482 1/20 0.40
HRH3 Q9Y5N1 2/20 0.40
MAPT P10636 3/20 0.39
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALDH1A1 P00352 2/20 0.39
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
S1PR1 P21453 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6042220 1.00 PPARA (0.41) PPARAPPARDPPARGKMT2AMEN1
SCHEMBL6041579 0.91 MEN1 (0.42) KMT2AMEN1MAPTNPC1RAB9A
SCHEMBL6043319 0.91 MEN1 (0.42) KMT2AMEN1MAPTNPC1RAB9A
SCHEMBL6041582 0.91 MEN1 (0.42) KMT2AMEN1MAPTNPC1RAB9A
SCHEMBL6041430 0.90 PPARA (0.43) PPARAPPARDKMT2AMEN1LMNA
SCHEMBL6041426 0.90 PPARA (0.43) PPARAPPARDKMT2AMEN1LMNA
SCHEMBL6956127 0.85 PPARA (0.40) PPARAPPARDPPARGKMT2AMEN1
SCHEMBL6041719 0.83 MEN1 (0.43) KMT2AMEN1POLBHRH3MAPT
SCHEMBL6043844 0.83 MEN1 (0.45) KMT2AMEN1MAPTNPC1HPGD
SCHEMBL3193386 0.82 RAB9A (0.45) KMT2AMEN1LMNAMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079533-A1 Methods of treating alzheimer's disease NIEMAN JAMES A 2006-04-13 US disclosed
WO-2002076440-A2 METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES ELAN PHARMACEUTICALS, INC. (US) 2002-10-03 WO disclosed
US-6150526-A Piperidine derivative having renin inhibiting activity HOFFMANN-LA ROCHE INC. (US) 2000-11-21 US disclosed
US-6051712-A PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS HOFFMANN-LA ROCHE INC. (US) 2000-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079533-A1 Methods of treating alzheimer's disease BACE1, PSEN1, PSEN2 PPARA 1956/4885PPARD 2835/4885PPARG 2073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.